Pharmacists contribute to the improved efficiency of medical practices in the outpatient cancer chemotherapy clinic

Journal of Evaluation in Clinical Practice

Volumn 18, Issue 4, 2012, Pages 753-760

  Iihara, Hirotoshi ^a   Ishihara, Masashi ^a   Matsuura, Katsuhiko ^a   Kurahashi, Sayoko ^a   Takahashi, Takao ^b   Kawaguchi, Yoshihiro ^b   Yoshida, Kazuhiro ^b   Itoh, Yoshinori ^a  

^a GIFU UNIVERSITY HOSPITAL   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

anti emetics; cancer chemotherapy; outcome; pharmacists; supportive care

Indexed keywords

ANTHRACYCLINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; MEDICAL STAFF; ONCOLOGY; OUTPATIENT DEPARTMENT; PATIENT EDUCATION; PHARMACIST; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME; WORKLOAD;

ADULT; AGED; ANTHRACYCLINES; ANTIEMETICS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; ECONOMICS, HOSPITAL; EFFICIENCY, ORGANIZATIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENT CLINICS, HOSPITAL; PHARMACISTS; PROFESSIONAL ROLE; QUALITY CONTROL; VOMITING;

EID: 84863332302     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/j.1365-2753.2011.01665.x     Document Type: Article

References (22)

1. Chewning, B., &, Wiederholt, J. B., (2003) Concordance in cancer medication management. Patient Education and Counseling, 50, 75-78.
2. Strasser, F., Sweeney, C., Willey, J., Benisch-Tolley, S., Palmer, J. L., &, Bruera, E., (2004) Impact of a half-day multidisciplinary symptom control and palliative care outpatient clinic in a comprehensive cancer center on recommendations, symptom intensity, and patient satisfaction: a retrospective descriptive study. Journal of Pain and Symptom Management, 27, 481-491.
3. Ikesue, H., &, Oishi, R., (2008) Oncology pharmacy specialists in oncology. Gan To Kagaku Ryoho. Cancer & Chemotherapy, 35, 578-582.
4. Gandhi, T. K., Bartel, S. B., Shulman, L. N., Verrier, D., Burdick, E., Cleary, A., Rothschild, J. M., Leape L. L., &, Bates D. W., (2005) Medication safety in the ambulatory chemotherapy setting. Cancer, 104, 2477-2483.
5. Shah, S., Dowell, J., &, Greene, S., (2006) Evaluation of clinical pharmacy services in a hematology/oncology outpatient setting. Annals of Pharmacotherapy, 40, 1527-1533.
6. Gilreath, J. A., Sageser, D. S., Jorgenson, J. A., &, Rodgers, G. M., (2008) Establishing an anemia clinic for optimal erythropoietic-stimulating agent use in hematology-oncology patients. Journal of the National Comprehensive Cancer Network, 6, 577-584.
7. Roila, F., Hesketh, P. J., &, Herrstedt, J., (2006) Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Annals of Oncology, 17, 20-28.
8. Kris, M. G., Hesketh, P. J., Somerfield, M. R., et al,. (2006) American society of clinical oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology, 24, 2932-2947.
9. Navari, R. M., (2007) Prevention of emesis from multiple-day and high-dose chemotherapy regimens. Journal of the National Comprehensive Cancer Network, 5, 51-59.
10. Hickok, J. T., Roscoe, J. A., Morrow, G. R., Bole, C. W., Zhao, H., Hoelzer, K. L., Dakhil, S. R., Moore, T., &, Fitch, T. R., (2005) 5-hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomized controlled trial. Lancet Oncology, 6, 765-772.
11. Okayasu, S., Nakamura, M., Chigusa, K., Sakurai, K., Matsuura, K., Yamamoto, M., Kinosada, Y., &, Itoh, Y., (2009) Development of computer-assisted biohazard safety cabinet for preparation and verification of injectable anticancer agents. Chemotherapy, 55, 234-240.
12. Ioannidis, J. P., Hesketh, P. J., &, Lau, J., (2000) Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence. Journal of Clinical Oncology, 18, 3409-3422.
13. Grunberg, S. M., (2007) Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Annals of Oncology, 18, 233-240.
14. Kaizer, L., Warr, D., Hoskins, P., Latreille, J., Lofters, W., Yau, J., Palmer, M., Zee, B., Levy, M., &, Pater, J., (1994) Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology, 12, 1050-1057.
15. Olver, I., Paska, W., Depierre, A., Seitz, J. F., Stewart, D. J., Goedhals, L., McQuade, B., McRae, J., &, Wilkinson, J. R., (1996) A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Annals of Oncology, 7, 945-952.
16. Goedhals, L., Heron, J. F., Kleisbauer, J. P., Pagani, O., &, Sessa, C., (1998) Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Annals of Oncology, 9, 661-666.
17. Geling, O., &, Eichler, H. G., (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. Journal of Clinical Oncology, 23, 1289-1294.
18. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. The New England Journal of Medicine, 342, 1554-1559.
19. 3 receptor antagonist in breast cancer patients with high-risk emetogenic chemotherapy. Anticancer Research, 29, 1721-1725.
20. Rapoport, B. L., Jordan, K., Boice, J. A., Taylor, A., Brown, C., Hardwick, J. S., Carides, A., Webb, T., &, Schmoll, H. J., (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Supportive Care in Cancer, 18, 423-431.
21. Warr, D. G., Hesketh, P. J., Gralla, R. J., et al,. (2005) Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. Journal of Clinical Oncology, 23, 2822-2830.
22. Saito, M., Aogi, K., Sekine, I., Yoshizawa, H., Yanagita, Y., Sakai, H., Inoue, K., Kitagawa, C., Ogura, T., &, Mitsuhashi, S., (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncology, 10, 115-124.